Dr. Reddy’s Laboratories
Latest, 22 Sept: Dr. Reddy’s to exclusively promote and distribute Takeda’s QDENGA vaccine in India.
Latest moves
Our read of each move first, where we have one; what the report said is marked Reported.
- Reported: Dr. Reddy’s exclusive QDENGA mandate strengthens its private-market vaccine distribution offering ahead of an anticipated H1 2027 India launch, contingent on local approvals.Reported: Dr. Reddy’s Laboratories will handle promotion and distribution of Takeda’s QDENGA dengue vaccine in India’s private pediatric and adult market, subject to local processes.Watch:
- Reported: Dr Reddy’s must prepare to replace revenue and field-force utilisation tied to the Novartis India brands while maintaining uninterrupted commercial execution through September 30, 2026.Reported: Dr Reddy’s ends Novartis India distribution pact after ownership change. Dr Reddy’s will continue commercialising the covered portfolio until September 30, 2026.Watch:
Background
From 5 stories, the newest dated 3 Oct 2026. Summary written 3 Oct 2026.
Dr. Reddy’s Laboratories is an Indian pharmaceutical company whose executives, alongside those of Sun Pharma, Cipla and Lupin, said faster approvals, stronger trials infrastructure and domestic acceptance are needed to accelerate innovation. [1] source: Business Standard
Show 3 more paragraphs and 5 sources
The government plans to certify 1,000 clinical trial centres. [1] source: Business Standard A May 2024 outlook listed Dr Reddy's with Alembic and Glenmark as planning new dermatology product launches, in a segment with a Rs 13,200 crore base per Pharmatrack April 2024 data and expected growth of 11-12 per cent. [2] source: Business Standard
In September 2026, Dr. Reddy’s said it will exclusively promote and distribute Takeda’s QDENGA dengue vaccine in India’s private market, with availability expected in H1 2027. [3] source: The Hindu BusinessLine[4] source: Business Today CDSCO marketing authorisation came in July 2026, and the vaccine is approved for individuals aged 4-60 years. [3] source: The Hindu BusinessLine[4] source: Business Today Takeda retains public-market rights, brand oversight and legal ownership, while Dr. Reddy’s deploys its physician, vaccinator and nationwide distribution network. [4] source: Business Today
Times of India reported in August 2026 that the Nestle India and Dr. Reddy’s joint venture launched Celevida GLP+. [5] source: Times of India
Sources
Questions about Dr. Reddy’s Laboratories
What is Dr. Reddy’s Laboratories' current strategy in India?
In September 2026, Dr. Reddy’s agreed to exclusively promote and distribute Takeda’s QDENGA dengue vaccine in India’s private market, targeting H1 2027 availability. [4] source: Business Today In August 2026, its joint venture with Nestle India launched Celevida GLP+. [5] source: Times of India
Stories that mention Dr. Reddy’s Laboratories
2 stories
Dr. Reddy’s Laboratories is named in these stories but is not their subject.